OncoSec Medical (ONCSQ) Stock Price, News & Analysis

Company Overview

OncoSec Medical Incorporated, headquartered in San Diego, California, is a clinical‐stage biotechnology company specializing in the development of novel immunotherapy approaches for the treatment of cancer. The company’s proprietary ImmunoPulse® platform employs electroporation technology to deliver cytokine‐encoding plasmid DNA directly into tumors, with the goal of stimulating a targeted immune response. OncoSec’s lead investigational therapy, tavokinogene telseplasmid (TAVO), encodes interleukin‐12 (IL‐12) and is being evaluated in multiple clinical trials in combination with immune checkpoint inhibitors across indications such as melanoma, triple‐negative breast cancer and Merkel cell carcinoma.

Founded in 2008, OncoSec has conducted early‐ and late‐stage clinical programs in the United States, Europe and Asia, collaborating with academic institutions and biopharma partners to advance its pipeline. The company’s development strategy emphasizes combination regimens that leverage TAVO’s local immune‐priming effects alongside systemic therapies, aiming to overcome tumor resistance and achieve durable clinical benefit. In addition to its clinical work, OncoSec continues to refine its electroporation device technology to enhance plasmid uptake and transgene expression.

Under the leadership of President and Chief Executive Officer Michael Kurland, OncoSec maintains a lean organizational structure focused on clinical execution and regulatory engagement. The company’s management team includes executives with expertise in oncology drug development, device engineering and global regulatory affairs. OncoSec is committed to advancing its immuno‐oncology platform with the objective of bringing new treatment options to patients with hard‐to‐treat solid tumors.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 62,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 8/07/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONCSQ
• CIK: 1444307
• Web: www.oncosec.com
• Phone: (855) 662-6732
• Fax: 858-430-3832
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,970,000
• Free Float: 5,884,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -30.04